Skip to main content
    S

    Skye Bioscience, Inc. Common Stock (SKYE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.06
    -0.03 (-2.29%)

    Market Cap: $4.83M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Skye Bioscience, Inc. Common Stock (SKYE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 16, 2026. Financial statements from company filings, amounts in US dollars.

    Skye Bioscience, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$55.92M, operating cash flow was -$43.06M and free cash flow was -$43.07M. The quarter ended Sep 30, 2026 had net income of $69.13K.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $58.16M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Cost of revenue$723.35K$298.64K$124.25K$115.00K$34.13K$1.87K$1.46K$1.54K$8.04K$14.92K
    Gross profit-$723.35K-$298.64K-$124.25K-$115.00K-$34.13K-$1.87K-$1.46K-$1.54K-$8.04K-$14.92K
    Research and development$42.36M$18.70M$5.82M$6.01M$2.93M$1.94M$2.24M$329.97K$311.30K$939.04K
    Operating income-$58.16M-$30.19M-$34.74M-$18.31M-$7.85M-$6.29M-$6.63M-$4.69M-$3.86M-$4.47M
    Net income-$55.92M-$26.57M-$37.64M-$19.48M-$8.52M-$6.56M$1.05M-$19.19M-$3.09M-$3.18M
    EBITDA-$55.20M-$25.29MN/AN/A-$7.72M-$5.85M$2.04M-$4.69M-$3.08MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    RevenueN/A$0$0$0$0$0$0$0$0$0$0$163.39K
    Gross profitN/AN/A-$172.89K-$180.01KN/A-$187.07K-$177.38K-$175.29K-$66.00K-$29.79K-$27.56K-$28.37K
    Operating income$26.32K-$11.06M-$12.67M-$14.90M-$13.26M-$18.24M-$11.76M-$10.67M-$4.97M-$8.41M-$6.15M-$4.09M
    Net income$69.13K-$10.79M-$12.51M-$14.44M-$12.75M-$17.62M-$11.10M-$9.75M-$3.90M-$7.90M-$5.02M-$4.42M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $189.65K by $5.69M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$28.31M$72.76M$11.94M$9.11M$9.86M$2.67M$2.00M$1.96M$557.22K$323.36K
    Current assets$27.09M$70.83M$11.65M$8.94M$9.61M$2.66M$1.99M$1.95M$555.81K$279.49K
    Cash and equivalents$5.88M$68.42M$1.26M$1.24M$8.98M$2.47M$1.83M$1.85M$259.95K$64.82K
    Total liabilities$8.29M$4.61M$14.07M$12.12M$3.99M$2.22M$1.45M$17.52M$1.36M$1.77M
    Short-term debt$189.65K$182.43K$4.44M$1.93M$2.06M$64.06KN/AN/A$235.00KN/A
    Long-term debtN/AN/AN/AN/AN/A$1.43M$387.07K$1.36MN/AN/A
    Shareholder equity$20.02M$68.15M-$2.13M-$3.01M$5.86M$450.79K$548.06K-$15.56M-$800.08K-$1.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$5.07M$11.03M$19.42M$28.31M$41.32M$52.16M$64.79M$72.76M$81.54M$87.26M$94.84M$11.94M
    Total liabilities$3.71M$11.53M$10.40M$8.29M$8.49M$8.48M$5.54M$4.61M$5.73M$14.45M$15.95M$14.07M
    Cash and equivalents$4.82M$8.07M$8.15M$5.88M$18.44M$23.84M$46.42M$68.42M$67.41M$74.12M$83.34M$1.26M
    Shareholder equity$1.36M-$497.31K$9.01M$20.02M$32.84M$43.68M$59.25M$68.15M$75.80M$72.81M$78.88M-$2.13M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$43.06M-$25.24M-$13.95M-$12.74M-$6.47M-$6.05M-$6.03M-$3.94M-$3.30M-$3.55M
    Capital expenditures$6.31K$1.60M$12.55K$28.06K$90.87K$7.23K$7.23K$4.38K$19.65K$11.12K
    Free cash flow-$43.07M-$26.84M-$13.96M-$12.77M-$6.57M-$6.06M-$6.04M-$3.95M-$3.32M-$3.56M
    Investing cash flow-$19.50M-$245.62K$6.60M$5.21M-$90.87K-$7.23K-$7.23K-$4.38K-$19.65K-$11.12K
    Financing cash flow$29.57K$83.56M$16.44M-$208.79K$13.08M$6.70M$6.00M$5.54M$3.51M$407.67K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.13M-$7.12M-$8.56M-$9.77M-$13.36M-$10.75M-$9.19B-$8.17M-$5.26M-$7.09M-$4.71M-$3.84M
    Capital expenditures$3$0$3$3$5$3$6.31M$50.02K$1.52M$32.46K$3.18K$7.01K
    Free cash flow-$5.13M-$7.12M-$8.56M-$9.77M-$13.36M-$10.75M-$9.19B-$8.22M-$6.78M-$7.13M-$4.71M-$3.85M
    Last 12 quarters

    Frequently Asked Questions About SKYE

    What is Skye Bioscience, Inc. Common Stock's annual revenue?

    Skye Bioscience, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Skye Bioscience, Inc. Common Stock profitable?

    No. Skye Bioscience, Inc. Common Stock reported net income of -$55.92M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SKYE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$43.06M minus capital expenditures of $6.31K produced free cash flow of -$43.07M.

    How much debt does Skye Bioscience, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $189.65K and cash and equivalents of $5.88M.